SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001169245-22-000124
Filing Date
2022-12-02
Accepted
2022-12-02 16:19:10
Documents
12
Period of Report
2022-11-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K phas-20221128.htm   iXBRL 8-K 37613
  Complete submission text file 0001169245-22-000124.txt   181885

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT phas-20221128.xsd EX-101.SCH 1902
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT phas-20221128_lab.xml EX-101.LAB 25848
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT phas-20221128_pre.xml EX-101.PRE 13581
6 EXTRACTED XBRL INSTANCE DOCUMENT phas-20221128_htm.xml XML 11434
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

IRS No.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 221442188
SIC: 2834 Pharmaceutical Preparations